Cargando…
FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier B.V.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521204/ http://dx.doi.org/10.1016/j.nmd.2020.08.228 |
| _version_ | 1783587927794647040 |
|---|---|
| author | Mellion, M. Kools, J. Mul, K. Ronco, L. Odueyungbo, A. Marshall, K. van Engelen, B. Cadavid, D. |
| author_facet | Mellion, M. Kools, J. Mul, K. Ronco, L. Odueyungbo, A. Marshall, K. van Engelen, B. Cadavid, D. |
| author_sort | Mellion, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7521204 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75212042020-09-29 FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1 Mellion, M. Kools, J. Mul, K. Ronco, L. Odueyungbo, A. Marshall, K. van Engelen, B. Cadavid, D. Neuromuscul Disord Article Published by Elsevier B.V. 2020-10 2020-09-28 /pmc/articles/PMC7521204/ http://dx.doi.org/10.1016/j.nmd.2020.08.228 Text en Copyright © 2020 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Mellion, M. Kools, J. Mul, K. Ronco, L. Odueyungbo, A. Marshall, K. van Engelen, B. Cadavid, D. FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1 |
| title | FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1 |
| title_full | FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1 |
| title_fullStr | FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1 |
| title_full_unstemmed | FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1 |
| title_short | FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1 |
| title_sort | fshd / opmd / myotonic dystrophy: p.229 open-label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with fshd1 |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521204/ http://dx.doi.org/10.1016/j.nmd.2020.08.228 |
| work_keys_str_mv | AT mellionm fshdopmdmyotonicdystrophyp229openlabelstudyoflosmapimodevaluatingsafetytolerabilityandchangesinbiomarkerandclinicaloutcomeassessmentsinsubjectswithfshd1 AT koolsj fshdopmdmyotonicdystrophyp229openlabelstudyoflosmapimodevaluatingsafetytolerabilityandchangesinbiomarkerandclinicaloutcomeassessmentsinsubjectswithfshd1 AT mulk fshdopmdmyotonicdystrophyp229openlabelstudyoflosmapimodevaluatingsafetytolerabilityandchangesinbiomarkerandclinicaloutcomeassessmentsinsubjectswithfshd1 AT roncol fshdopmdmyotonicdystrophyp229openlabelstudyoflosmapimodevaluatingsafetytolerabilityandchangesinbiomarkerandclinicaloutcomeassessmentsinsubjectswithfshd1 AT odueyungboa fshdopmdmyotonicdystrophyp229openlabelstudyoflosmapimodevaluatingsafetytolerabilityandchangesinbiomarkerandclinicaloutcomeassessmentsinsubjectswithfshd1 AT marshallk fshdopmdmyotonicdystrophyp229openlabelstudyoflosmapimodevaluatingsafetytolerabilityandchangesinbiomarkerandclinicaloutcomeassessmentsinsubjectswithfshd1 AT vanengelenb fshdopmdmyotonicdystrophyp229openlabelstudyoflosmapimodevaluatingsafetytolerabilityandchangesinbiomarkerandclinicaloutcomeassessmentsinsubjectswithfshd1 AT cadavidd fshdopmdmyotonicdystrophyp229openlabelstudyoflosmapimodevaluatingsafetytolerabilityandchangesinbiomarkerandclinicaloutcomeassessmentsinsubjectswithfshd1 |